Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: eloxxpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2021 | $4.00 | Outperform | Oppenheimer |
| 11/18/2021 | $2.00 → $1.00 | Neutral | HC Wainwright & Co. |
| 11/11/2021 | $3.00 → $2.00 | Neutral | HC Wainwright & Co. |
| 6/30/2021 | $3.10 | Buy | Mizuho |
Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00
HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously
HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously
Mizuho initiated coverage of Eloxx Pharmaceuticals with a rating of Buy and set a new price target of $3.10
B. Riley Securities initiated coverage of Eloxx Pharmaceuticals with a rating of Buy and set a new price target of $5.00
NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
NT 10-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
S-3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
S-8 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)